INDICATIONS

FULL PRESCRIBING INFORMATION

PATIENT INFORMATION

VISIT HEALTHCARE PROFESSIONAL SITE
Potential KRAZATI® patient wearing a red top and leather jacket against a blue background.
Potential KRAZATI® patient wearing a red top and leather jacket against a blue background.

Support 
& RESOURCES

 

 

Not an actual patient.

Explore resources to help ensure that you are never alone in your NSCLC journey.

BMS Access Support

At Bristol Myers Squibb, we provide support with purpose

A woman holding a banner with the Bristol Myers Squibb® Access Support logo.

The BMS Access Support program is dedicated to helping patients access their prescribed BMS medications. BMS Access Support provides resources to help patients understand their insurance coverage, offers educational materials to support patients throughout their treatment journey, and provides information on financial support options, including co-pay assistance for eligible commercially-insured patients.

For more information, ask your doctor, visit BMS Access Support by clicking the button below, or call BMS Access Support at 1-800-861-0048, 8 AM to 8 PM ET, Monday to Friday.

-

Visit www.BMSAccessSupport.com

Downloadable Resources

Download these documents to guide you through your treatment with KRAZATI® (adagrasib)

Downloadable document for the KRAZATI® patient brochure for KRAS G12-positive non-small cell lung cancer.

KRAZATI Patient Brochure

English Version Download Now ❯

Spanish Version Download Now ❯

Downloadable document for the frequently asked questions about KRAZATI® for KRAS G12-positive non-small cell lung cancer.

Downloadable KRAZATI FAQs

Download Now ❯

Please call 1-800-321-1335 to speak with a Medical Information Professional about KRAZATI, or 1-800-721-5072 to report an adverse event/product complaint. You can also directly report an adverse event/product complaint by clicking here.

Community Support

Discover additional resources and a community of support through the links below.

Potential KRAZATI® patient in a red top and leather jacket fist-bumping another potential patient in a patterned blouse.

Cancer Support Community

As the largest professionally led nonprofit network of cancer support worldwide, Cancer Support Community (CSC) is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community.

Educational Support ❯

Emotional Support ❯

CancerCare

CancerCare is the leading national organization providing free, professional support services and information to help people manage the emotional, practical, and financial challenges of cancer.

Educational/Emotional Support ❯

GO2 Foundation for Lung Cancer

Founded by patients and survivors, GO2 Foundation for Lung Cancer transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

Educational Support ❯

Emotional Support ❯

Lungevity Foundation

Lungevity Foundation is the nation’s leading lung cancer organization focused on improving outcomes for people with lung cancer through research, education, policy initiatives, and support for patients, survivors, and caregivers.

Educational/Emotional Support ❯

KRAS Kickers

A nonprofit for KRAS oncogene patients, survivors, and their loved ones. We bring together research, information, and hope for all with a KRAS biomarker, inspiring our community to fight in our common battle.

Educational Support ❯

Emotional Support ❯

Lung Cancer Research Foundation®

The mission of Lung Cancer Research Foundation (LCRF) is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer.

Educational Support ❯

Emotional Support ❯

One Cancer Place

One Cancer Place, the first patient-powered cancer learning community, is on a mission to create a global, all-cancer, patient-led learning community connected to innovative treatment offerings.

Educational/Emotional Support ❯

NSCLC=non-small cell lung cancer.

Bristol Myers Squibb does not endorse these organizations. The information/links provided by Bristol Myers Squibb are meant for informational purposes only and are not meant to replace a physician’s medical advice.

IMPORTANT SAFETY INFORMATION

KRAZATI may cause serious side effects, including stomach and intestinal (gastrointestinal) problems, changes in the electrical activity of the heart called QTc prolongation, liver problems, and lung or breathing problems.

Before taking KRAZATI, tell your healthcare provider about all of your medical conditions, including if you:

 
  • have any heart problems, including heart failure and congenital long QT syndrome
  • have liver problems
  • are pregnant or plan to become pregnant. It is not known if KRAZATI can harm your unborn baby
  • are breastfeeding or plan to breastfeed. It is not known if KRAZATI passes into your breastmilk. Do not breastfeed during treatment and for 1 week after your last dose of KRAZATI

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. KRAZATI can affect the way other medicines work, and other medicines can affect how KRAZATI works.

KRAZATI can cause serious side effects, including:

 
  • Stomach and intestinal (gastrointestinal) problems. Stomach and intestinal side effects including nausea, diarrhea, or vomiting, are common with KRAZATI but can also sometimes be severe. KRAZATI can also cause serious stomach and intestinal side effects such as bleeding, obstruction, inflammation of the colon (colitis), and narrowing (stenosis)

    • Call your healthcare provider if you develop any of the signs or symptoms of stomach or intestinal problems listed above during treatment with KRAZATI

    • Your healthcare provider may prescribe an antidiarrheal medicine or anti-nausea medicine, or other treatment, as needed
       
  • Changes in the electrical activity of your heart called QTc prolongation. Certain changes can occur in the electrical activity of your heart during treatment with KRAZATI, and can be seen on a test called an electrocardiogram (ECG or EKG). QTc prolongation can increase your risk for irregular heartbeats that can be life-threatening, such as torsades de pointes, and can lead to sudden death

    • You should not take KRAZATI if you have congenital long QT syndrome or if you currently have QTc prolongation. See “Before taking KRAZATI, tell your healthcare provider about all of your medical conditions, including if you:”

      • Your healthcare provider should monitor the electrical activity of your heart and the levels of body salts in your blood (electrolytes) especially potassium and magnesium before starting and during treatment with KRAZATI if you have heart failure, a slow heart rate, abnormal levels of electrolytes in your blood, or if you take a medicine that can prolong the QT interval of your heartbeat

      • Tell your healthcare provider if you feel dizzy, lightheaded, or faint, or if you get abnormal heartbeats during treatment with KRAZATI
  • Liver problems. Abnormal liver blood test results are common with KRAZATI and can sometimes be severe. Your healthcare provider should do blood tests before starting and during treatment with KRAZATI to check your liver function. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems, including:

    • your skin or white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, pain, aching, or tenderness on the right side of your stomach area (abdomen)
       
  • Lung or breathing problems. KRAZATI may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever

The most common side effects

 
  • The most common side effects of KRAZATI when used alone for NSCLC include: nausea, diarrhea, vomiting, tiredness, muscle and bone pain, kidney problems, swelling, decreased appetite, trouble breathing

  • The most common side effects when KRAZATI is used in combination with cetuximab for CRC include: skin rash, nausea, diarrhea, vomiting, tiredness, muscle and bone pain, headache, dry skin, stomach pain, decreased appetite, swelling, low red blood cell count, cough, dizziness, constipation, nerve damage in the arms and legs

Certain abnormal blood test results are common during treatment with KRAZATI, when used alone or in combination with cetuximab. Your healthcare provider will monitor you for abnormal blood tests and treat you if needed.

KRAZATI may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects of KRAZATI. Call your doctor for medical advice about side effects. You may report side effects to the FDA. Visit  fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to 1-844-647-2841.

Please see KRAZATI Patient Information. 

1914-US-2400480  10/24

Bristol Myers Squibb logo

Site Map     Legal Notice     Privacy Policy     Your Privacy Choices    

© 2024 Mirati Therapeutics, Inc., a Bristol Myers Squibb company.
KRAZATI® and the related logo are registered trademarks of Mirati Therapeutics, Inc.

This website is intended for U.S. residents 18 years of age or older.

1914-US-2400471 10/24